Novo Nordisk stock faces an FDA delay as Q3 results approach
Published on 10/04/2026 at 15:22 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Novo Nordisk (ISIN DK0062498333) carries a market capitalization of DKK 1.12 trillion on its primary Nasdaq Copenhagen listing as of October 2, 2026. The FDA extended its review of denecimig, the company's hemophilia A treatment, because of facility remediation, according to FinanzNachrichten on October 2, 2026.
Denecimig review moves into 2027
Novo said the US review remains tied to manufacturing-site remediation, while the FDA identified efficacy and safety data as free of deficiencies in the submitted application. The company continues to target a US launch in the first half of 2027, subject to the regulatory decision, FinanzNachrichten reported.
The update changes the timing of a potential product launch but does not change Novo Nordisk's 2026 financial outlook. Denecimig received a positive CHMP opinion on September 17, 2026, and remains under review in other jurisdictions.
Q2 growth meets a tougher guide
Novo Nordisk's adjusted sales increased 7 percent at constant exchange rates to DKK 78.5 billion in Q2 2026, while adjusted operating profit rose 11 percent at constant exchange rates, according to Yahoo Finance on September 17, 2026.
Management's adjusted sales and operating-profit guidance for 2026 was 0 percent to -6 percent growth at constant exchange rates. The contrast between 7 percent Q2 sales growth and a full-year range that permits a decline puts pricing, competition and the second half of the year at the center of the investment case.
Analysts stay cautious before November
MarketScreener reported on September 22, 2026, that JP Morgan kept Novo Nordisk at Neutral with a DKK 260 price target. The same published consensus showed a HOLD rating from 25 analysts and an average target of DKK 307.56.
Jefferies also retained its Hold rating on September 22, 2026, while cutting its target from DKK 285 to DKK 275, according to MarketScreener. The revision shows how the market is weighing obesity-drug growth against patent, pricing and execution risks.
Q3 results arrive November 4
Novo Nordisk plans to announce results for the first three quarters of 2026 on November 4, 2026, at 7:30 a.m. CEST, according to its financial results calendar. That report will test whether the Q2 sales pace can offset the company's full-year pricing and competition pressures.
Market value sets the checkpoint
Novo Nordisk's DKK 1.12 trillion market capitalization as of October 2, 2026, gives the November report a clear valuation backdrop. The key figures are the Q3 sales mix, adjusted operating profit and any change to the 0 percent to -6 percent full-year guidance.
Novo Nordisk stock facts
- Company: Novo Nordisk A/S
- ISIN: DK0062498333
- Ticker: NOVO B
- Trading venue: Nasdaq Copenhagen
- Market capitalization: DKK 1.12 trillion (as of October 2, 2026)
- Sector / Industry: Healthcare / Pharmaceuticals
- Index membership: OMX Copenhagen 25
Upcoming dates for Novo Nordisk stock
- November 4, 2026: Q3 2026 financial results
